Early Symptomatic Improvement Is Informing Long-Term Quality-of-Life Outcomes with Filgotinib Treatment in Ulcerative Colitis: A Post Hoc Analysis of the SELECTION and SELECTIONLTE Trials
Inflammatory Intestinal Diseases · 02.06.2026 · 11 (1) · 270-276
DOI: 10.1159/000552558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Intestinal Diseases, online erschienen am 02.06.2026. Verfasst von Fumihito Hirai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Ulcerative colitis is a chronic inflammatory condition of the colon that significantly impairs quality-of-life. While filgotinib (FIL) has shown long-term efficacy in improving disease-specific quality-of-life via Inflammatory Bowel Disease Questionnaire (IBDQ) total scores, its impact on individual bowel/systemic symptoms remains unclear. This post hoc analysis assessed FIL’s long-term effects on these symptoms and explored factors associated with sustained remission.
Methods
This analysis included 148 patients from SELECTION trial patients who completed induction and maintenance phases, enrolled in SELECTIONLTE, and continued 200-mg FIL (FIL200) without treatment change. Changes from induction baseline in IBDQ total and subscores (bowel/systemic symptoms) were assessed at Week 10, 58, and long-term extension (LTE) Week 96. Remission was defined as IBDQ ≥170 and partial Mayo Clinic Score (pMCS) ≤1 at each timepoint.
Results
At Week 10, for patients with vs. without pMCS remission, the mean ± standard deviation change in IBDQ total score was 72.98 ± 39.37 vs. 53.46 ± 31.75, respectively. At Week 58, it was 80.42 ± 34.44 vs. 49.97 ± 38.24 and at LTE Week 96, it was 84.14 ± 35.22 vs. 49.10 ± 28.00, respectively. Overall, bowel and systemic symptom scores were numerically higher in patients with vs. without pMCS remission at Week 10, slightly increased at Week 58, and remained consistent at LTE Week 96. Symptomatic remission at Week 10 and IBDQ remission at LTE Week 96 were associated significantly (odds ratio [95% confidence interval]: 2.288 [1.003–5.216]; p = 0.049).
Conclusions
FIL200 improved bowel and systemic symptoms beyond rectal bleeding and stool frequency, enhancing disease-specific quality-of-life. Week 10 symptomatic remission was marginally associated with higher odds of long-term IBDQ remission, suggesting that early symptomatic remission provides clinically relevant information on sustained quality-of-life improvement.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
- Global Medical Affairs, Alfasigma GmbH, Munich, Germany.
- Medical Affairs, Gilead Sciences K.K., Tokyo, Japan.
- Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Zitieren
APA
Hirai, F., Rudolph, C., Kaise, T., & Hibi, T. (2026). Early Symptomatic Improvement Is Informing Long-Term Quality-of-Life Outcomes with Filgotinib Treatment in Ulcerative Colitis: A Post Hoc Analysis of the SELECTION and SELECTIONLTE Trials. Inflammatory Intestinal Diseases, 11(1), 270-276. https://doi.org/10.1159/000552558
Vancouver
Hirai F, Rudolph C, Kaise T, Hibi T. Early Symptomatic Improvement Is Informing Long-Term Quality-of-Life Outcomes with Filgotinib Treatment in Ulcerative Colitis: A Post Hoc Analysis of the SELECTION and SELECTIONLTE Trials. Inflammatory Intestinal Diseases. 2026;11(1):270-276. doi:10.1159/000552558
BibTeX
@article{Hirai2026,
author = {Hirai, Fumihito and Rudolph, Christine and Kaise, Toshihiko and Hibi, Toshifumi},
title = {Early Symptomatic Improvement Is Informing Long-Term Quality-of-Life Outcomes with Filgotinib Treatment in Ulcerative Colitis: A Post Hoc Analysis of the SELECTION and SELECTIONLTE Trials},
journal = {Inflammatory Intestinal Diseases},
year = {2026},
volume = {11},
number = {1},
pages = {270--276},
doi = {10.1159/000552558}
}
EUVIMED